{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:32:41Z","timestamp":1786991561417,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jbo.2024.100631","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T18:28:21Z","timestamp":1724524101000},"page":"100631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Groenlandicine enhances cisplatin sensitivity in cisplatin-resistant osteosarcoma cells through the BAX\/Bcl-2\/Caspase-9\/Caspase-3 pathway"],"prefix":"10.1016","volume":"48","author":[{"given":"Zihao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9784-1515","authenticated-orcid":false,"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jbo.2024.100631_b0005","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1007\/s00432-023-04614-4","article-title":"Targeted therapy for osteosarcoma: a review","volume":"149","author":"Li","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2024.100631_b0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11914-023-00803-9","article-title":"Advances in osteosarcoma","volume":"21","author":"Panez-Toro","year":"2023","journal-title":"Curr. Osteoporos. Rep."},{"issue":"12","key":"10.1016\/j.jbo.2024.100631_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121595","article-title":"Epigenetic changes associated with osteosarcoma: a comprehensive review","volume":"12","author":"Twenhafel","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jbo.2024.100631_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jbo.2024.100631_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-43032-0_1","article-title":"Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective","volume":"1257","author":"Benjamin","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"Suppl 2","key":"10.1016\/j.jbo.2024.100631_b0030","doi-asserted-by":"crossref","first-page":"e28352","DOI":"10.1002\/pbc.28352","article-title":"Osteosarcoma","volume":"68","author":"Eaton","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.jbo.2024.100631_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26113375","article-title":"DNA-topology simplification by topoisomerases","volume":"26","author":"Hanke","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.jbo.2024.100631_b0040","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1080\/14756366.2020.1821676","article-title":"DNA topoisomerases as molecular targets for anticancer drugs","volume":"35","author":"Buzun","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.jbo.2024.100631_b0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/cancers5020662","article-title":"Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse","volume":"5","author":"Nguyen","year":"2013","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.jbo.2024.100631_b0050","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.2147\/IJN.S377149","article-title":"Advances in antitumor nano-drug delivery systems of 10-hydroxycamptothecin","volume":"17","author":"Chen","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.jbo.2024.100631_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031532","article-title":"Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy","volume":"23","author":"Dasari","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2024.100631_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jbo.2024.100631_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115323","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100631_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbscr.2020.100054","article-title":"Cisplatin's dual-effect on the circadian clock triggers proliferation and apoptosis","volume":"9","author":"Sadiq","year":"2020","journal-title":"Neurobiol. Sleep Circad. Rhythms"},{"key":"10.1016\/j.jbo.2024.100631_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119430","article-title":"Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy","volume":"277","author":"Mirzaei","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jbo.2024.100631_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-021-01771-9","article-title":"Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT","volume":"21","author":"Qi","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jbo.2024.100631_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119705","article-title":"Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer","volume":"280","author":"Alam","year":"2021","journal-title":"Life Sci."},{"issue":"20","key":"10.1016\/j.jbo.2024.100631_b0090","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1097\/CM9.0000000000002800","article-title":"Research progress in the mechanism and treatment of osteosarcoma","volume":"136","author":"Bian","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.jbo.2024.100631_b0095","doi-asserted-by":"crossref","first-page":"1117867","DOI":"10.3389\/fonc.2023.1117867","article-title":"Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities","volume":"13","author":"Du","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2024.100631_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154743","article-title":"MicroRNAs as the pivotal regulators of cisplatin resistance in osteosarcoma","volume":"249","author":"Moghbeli","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.jbo.2024.100631_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11864-021-00839-y","article-title":"Long non-coding RNAs in cisplatin resistance in osteosarcoma","volume":"22","author":"Ferretti","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2024.100631_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122878","article-title":"Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies","volume":"13","author":"Hattinger","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jbo.2024.100631_b0115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.20517\/cdr.2022.18","article-title":"An overview of resistance to chemotherapy in osteosarcoma and future perspectives","volume":"5","author":"Garcia-Ortega","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"10.1016\/j.jbo.2024.100631_b0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbrc.2019.03.191","article-title":"Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model","volume":"513","author":"Higuchi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"45","key":"10.1016\/j.jbo.2024.100631_b0125","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aba783","article-title":"Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy","volume":"31","author":"Li","year":"2020","journal-title":"Nanotechnology"},{"issue":"15","key":"10.1016\/j.jbo.2024.100631_b0130","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2021.1936499","article-title":"State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma","volume":"22","author":"Meazza","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.jbo.2024.100631_b0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajco.13449","article-title":"Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance","volume":"17","author":"Usman","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100631_b0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-6-101","article-title":"Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors","volume":"6","author":"Campbell","year":"2006","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2024.100631_b0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/1078155218790798","article-title":"Vincristine, irinotecan, and temozolomide treatment for refractory\/relapsed pediatric solid tumors: A single center experience","volume":"25","author":"B\u00fcy\u00fckkapu Bay","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jbo.2024.100631_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114897","article-title":"Simultaneous screening, identification, quantitation, and activity evaluation of six acetylcholinesterase (AChE) inhibitors in Coptidis Rhizoma by online UPLC-DAD coupled with AChE biochemical detection","volume":"219","author":"Tan","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jbo.2024.100631_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.107927","article-title":"The role and potential of computer-aided drug discovery strategies in the discovery of novel antimicrobials","volume":"169","author":"Oselusi","year":"2024","journal-title":"Comput. Biol. Med."},{"issue":"18","key":"10.1016\/j.jbo.2024.100631_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184331","article-title":"Molecular Docking: Shifting Paradigms in Drug Discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jbo.2024.100631_b0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13880209.2019.1577466","article-title":"Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology","volume":"57","author":"Wang","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.jbo.2024.100631_b0170","doi-asserted-by":"crossref","first-page":"9987097","DOI":"10.1155\/2021\/9987097","article-title":"Pharmacokinetics and pharmacological activities of berberine in diabetes mellitus treatment","volume":"2021","author":"Han","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.jbo.2024.100631_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.jbo.2024.100631_b0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.jbo.2024.100631_b0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2005.05.039","article-title":"Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells","volume":"237","author":"Cho","year":"2006","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.jbo.2024.100631_b0190","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1078-0432.CCR-08-2581","article-title":"Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma","volume":"15","author":"Michaud","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:45:06Z","timestamp":1732668306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":38,"alternative-id":["S2212137424001118"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100631","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Groenlandicine enhances cisplatin sensitivity in cisplatin-resistant osteosarcoma cells through the BAX\/Bcl-2\/Caspase-9\/Caspase-3 pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100631"}}